RAPID MICRO BIOSYSTEMS INC-A (RPID) Stock Fundamental Analysis
USA - NASDAQ:RPID - US75340L1044 - Common Stock
2.99 USD
+0.08 (+2.75%)
RPID gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. RPID may be in some trouble as it scores bad on both profitability and health. RPID is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RPID has reported negative net income.
In the past year RPID has reported a negative cash flow from operations.
RPID had negative earnings in each of the past 5 years.
In the past 5 years RPID always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -58.36%, RPID is not doing good in the industry: 84.48% of the companies in the same industry are doing better.
RPID has a worse Return On Equity (-80.87%) than 77.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.36% | ||
| ROE | -80.87% | ||
| ROIC | N/A |
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RPID has a worse Gross Margin (7.53%) than 87.93% of its industry peers.
RPID does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RPID does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RPID has more shares outstanding
The number of shares outstanding for RPID has been increased compared to 5 years ago.
The debt/assets ratio for RPID is higher compared to a year ago.
2.2 Solvency
RPID has an Altman-Z score of -6.38. This is a bad value and indicates that RPID is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.38, RPID is not doing good in the industry: 87.93% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that RPID is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, RPID is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.38 |
ROIC/WACCN/A
WACC10.6%
2.3 Liquidity
RPID has a Current Ratio of 3.67. This indicates that RPID is financially healthy and has no problem in meeting its short term obligations.
RPID has a Current ratio of 3.67. This is in the better half of the industry: RPID outperforms 62.07% of its industry peers.
RPID has a Quick Ratio of 2.41. This indicates that RPID is financially healthy and has no problem in meeting its short term obligations.
RPID has a Quick ratio (2.41) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.67 | ||
| Quick Ratio | 2.41 |
3. Growth
3.1 Past
RPID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.68%, which is quite good.
The Revenue has grown by 22.55% in the past year. This is a very strong growth!
RPID shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.18% yearly.
EPS 1Y (TTM)13.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
Revenue 1Y (TTM)22.55%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%9.73%
3.2 Future
Based on estimates for the next years, RPID will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.48% on average per year.
The Revenue is expected to grow by 22.69% on average over the next years. This is a very strong growth
EPS Next Y6.97%
EPS Next 2Y9.63%
EPS Next 3Y10.48%
EPS Next 5YN/A
Revenue Next Year15.94%
Revenue Next 2Y18.92%
Revenue Next 3Y22.69%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RPID. In the last year negative earnings were reported.
Also next year RPID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.63%
EPS Next 3Y10.48%
5. Dividend
5.1 Amount
RPID does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RPID (10/31/2025, 8:12:17 PM)
2.99
+0.08 (+2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners58.09%
Inst Owner Change-24.59%
Ins Owners4.1%
Ins Owner Change5.48%
Market Cap132.19M
Revenue(TTM)30.29M
Net Income(TTM)-44110000
Analysts84
Price Target8.16 (172.91%)
Short Float %0.92%
Short Ratio4.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.55%
Min EPS beat(2)-4.49%
Max EPS beat(2)5.59%
EPS beat(4)3
Avg EPS beat(4)1.84%
Min EPS beat(4)-4.49%
Max EPS beat(4)6.22%
EPS beat(8)5
Avg EPS beat(8)1.97%
EPS beat(12)7
Avg EPS beat(12)2.46%
EPS beat(16)8
Avg EPS beat(16)-3.45%
Revenue beat(2)2
Avg Revenue beat(2)4.13%
Min Revenue beat(2)1.23%
Max Revenue beat(2)7.03%
Revenue beat(4)4
Avg Revenue beat(4)6.34%
Min Revenue beat(4)1.23%
Max Revenue beat(4)13.82%
Revenue beat(8)8
Avg Revenue beat(8)5.39%
Revenue beat(12)11
Avg Revenue beat(12)7.75%
Revenue beat(16)12
Avg Revenue beat(16)2.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.36 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.42 | ||
| P/tB | 2.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0.69
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.36% | ||
| ROE | -80.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.53% | ||
| FCFM | N/A |
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29.71% | ||
| Cap/Sales | 3.32% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.67 | ||
| Quick Ratio | 2.41 | ||
| Altman-Z | -6.38 |
F-Score4
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)112.45%
Cap/Depr(5y)118.7%
Cap/Sales(3y)17.47%
Cap/Sales(5y)14.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
EPS Next Y6.97%
EPS Next 2Y9.63%
EPS Next 3Y10.48%
EPS Next 5YN/A
Revenue 1Y (TTM)22.55%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%9.73%
Revenue Next Year15.94%
Revenue Next 2Y18.92%
Revenue Next 3Y22.69%
Revenue Next 5YN/A
EBIT growth 1Y15.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.19%
OCF growth 3YN/A
OCF growth 5YN/A
RAPID MICRO BIOSYSTEMS INC-A / RPID FAQ
Can you provide the ChartMill fundamental rating for RAPID MICRO BIOSYSTEMS INC-A?
ChartMill assigns a fundamental rating of 2 / 10 to RPID.
What is the valuation status of RAPID MICRO BIOSYSTEMS INC-A (RPID) stock?
ChartMill assigns a valuation rating of 0 / 10 to RAPID MICRO BIOSYSTEMS INC-A (RPID). This can be considered as Overvalued.
What is the profitability of RPID stock?
RAPID MICRO BIOSYSTEMS INC-A (RPID) has a profitability rating of 0 / 10.
How financially healthy is RAPID MICRO BIOSYSTEMS INC-A?
The financial health rating of RAPID MICRO BIOSYSTEMS INC-A (RPID) is 3 / 10.